Abstract: A light control sheet including a first transparent electrode layer, a second transparent electrode layer, a light control layer including a resin layer which is formed between the first and second transparent electrode layers and includes a liquid crystal composition in holes formed in the resin layer, the liquid crystal composition including liquid crystal molecules, and a first alignment layer formed between the first transparent electrode layer and the light control layer such that a haze of the light control layer is increased upon application of a voltage to the first transparent electrode layer. The light control layer includes a first high-density portion and a low-density portion, and the first high-density portion is in contact with the first alignment layer and includes the liquid crystal composition at a density higher than a density of the liquid crystal composition in the low-density portion per unit thickness of the light control layer.

Abstract: A seat pad manufacturing method is provided. The method includes disposing a sheet member inside a foaming mold for shaping a seat pad, then injecting a foaming resin material into the foaming mold and foaming a resin foamed body through mold clamping, and demolding the resin foamed body in a state in which the sheet member is buried in the resin foamed body. Both end parts of the sheet member in the right-left direction and both end parts of the sheet member in the extending direction are each temporarily fastened to the surface of the mold through a fastener. The foaming resin material is injected into a space between the mold surface and the sheet member. A central part of the sheet member deforms into a shape curved in a convex shape as the sheet member is pressed upward through expansion of the foaming resin material.

Abstract: Provided is a tetrahydrothienopyrimidinesulfonamide compound having a PARG inhibitory action useful as an active ingredient of a pharmaceutical composition for treating cancer, a pharmaceutical composition for enhancing an effect of an anticancer agent, and/or a pharmaceutical composition for enhancing an effect of radiotherapy. The tetrahydrothienopyrimidinesulfonamide compound of the present invention is a compound of Formula (I) or a salt thereof. (In Formula, L1 is methylene or the like, L2 is methylene or the like, R1 is an aromatic heterocyclic group which may have a substituent or the like, R2 is a non-aromatic heterocyclic group which may have a substituent, an aromatic heterocyclic group which may have a substituent, or the like, and R3 is 1-methylcyclopropyl or the like.

Abstract: A vehicle control device configured to control supply of electric power generated by a solar panel mounted on a vehicle includes a supply destination setting unit configured to set, based on a condition of the vehicle, a target device that is a destination for the supply of the electric power generated by the solar panel, a target setting unit configured to set, depending on the target device set by the supply destination setting unit, target output electric power to be output from the solar panel to the target device, and a power controller configured to control the electric power to be supplied from the solar panel to the target device based on the target output electric power set by the target setting unit.

Abstract: The present invention is related to a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of aminocarboxymuconate semialdehyde decarboxylase (ACMSD).

Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Abstract: The present invention is related to a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of aminocarboxymuconate semialdehyde decarboxylase (ACMSD).

Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Abstract: The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Abstract: The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

Abstract: The present invention is related to a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of aminocarboxymuconate semialdehyde decarboxylase

Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Abstract: The present invention also contemplates a method of treating a human patient with acute kidney injury or reducing the likelihood of developing acute kidney injury in a human patient at risk of developing acute kidney injury comprising administering to the patient a poly-ADP ribose polymerase (PARP) inhibitor in a therapeutically effective dose so as to thereby treat the patient.

Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Abstract: The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

Abstract: The present invention is related to a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of aminocarboxymuconate semialdehyde decarboxylase (ACMSD).

Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Abstract: [Problem] To provide a compound which is useful as an active ingredient for a pharmaceutical composition for preventing or treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. [Means for Solution] The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic M3 receptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-Acylaminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.